PARIS (Reuters) - French drugmaker Sanofi said it won approval from the Japanese government for its Lyxumia drug for the treatment of Type 2 diabetes in combination with basal insulin.
Lyxumia is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic’s blood sugar level climbs too high.
Lyxumia is now approved in Mexico, the European Union, Australia and Japan, Sanofi said in a statement on Friday. A new drug application for lixisenatide in the United States is currently being reviewed, it added.
Reporting by James Regan; Editing by Dominique Vidalon